A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Hepatic Insufficiency

Interventions

DRUG

CP-690,550

Single 10 mg dose of CP-690,550

DRUG

CP-690,550

Single 10 mg dose of CP-690,550

DRUG

CP-690,550

Single 10 mg dose of CP-690,550

Trial Locations (1)

Pfizer Investigational Site, South Miami